Published 2020-07-20
Sri Suryanti Hasrayati Agustina Sri Mulyati


Objective: To obtain FGFR3 and p53 immunohistochemistry of PUNLM and UBC basic data profile. Material & Methods: This retrospective observational analytic study used a cross-sectional design on formalin-fixed paraffin-embedded (FFPE) from patients diagnosed as PUNLMP and UBC then performed FGFR3 and p53 immunohistochemical staining. Statistical analysis of immunoexpression data using SPSS 24.0. Results: There are three main immunohistochemistry pattern profiles of PUNLMP and UBC in this research data, i.e. FGFR3+ p53+, FGFR+ p53- and FGFR3- p53+. There were no Cis sample obtained. FGFR+ was showed in PUNLMP, LG-PUC, HG-PUC, IUBC (pT1, pT2, pT3, pT4) with decreased percentage sequentially. As many as 51 of 54(94.44%) IUBC samples showed combination pattern with p53+ while 3 other samples were p53-. Conclusion: The FGFR3 and p53 immunohistochemistry profile, separately or as a pattern of combination, is in accordance with the oncogenesis molecular pathway of  UBC.



urothelial bladder cancer, FGFR3, p53, immunohistochemistry


Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: Costs and considerations of caring for this disease. Eur Urol. 2014; 66: 253–62.

Jacobs, B.L., Lee, C.T., Montie JE. Bladder Cancer in 2010. CA Cancer J Clin. 2010; 60(4): 244–72.

Zhao M, He X-L, Teng X-D. Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. Chin J Cancer Res. 2016; 28(1): 92–8.

Umbas R, Hardjowijoto S, Mochtar CA, Safriadi F, Djatisoesanto W, Agung A, et al. Panduan penanganan kanker kandung kemih tipe urotelial. 2014.

Netto GJ. Molecular Pathology of Bladder Cancer. Surg Pathol Clin. 2012; 5(4): 843–58.

Sanguedolce F, Bufo P, Carrieri G, Cormio L. Predictive markers in bladder cancer: Do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci. 2014; 51(5): 291–304.

Afonso JP, Freitas R, Lobo F. Urothelial bladder cancer progression: lessons learned from the bench. Journal of Cancer Metastasis and Treatment. 2015 July 1; 1(2): 1-10.

Kang HW, Kim YH, Jeong P, Park C, Kim WT, Ryu DH, et al. Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncol Lett. 2017; 14: 3817–24.

Isharwal S, Konety B. Non-muscle invasive bladder cancer risk stratification. Indian J Urol. 2015; 31(4): 289–96.

Conditions G. Genetics Home Reference FGFR3 gene. 380.

Kamat AM, Bağcıoğlu M, Huri E. What is new in non-muscle-invasive bladder cancer in 2016. Turk Urol Derg. 2017; 43(1): 9–13.

Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013; 3(9): 1058–71.

Cheng L, Lopez-Beltran A, MacLennan GT, Montironi R, Bostwick DG. Neoplasm of the urinary bladder. In: Urologic Surgical Pathology. Second. 2008. p. 2008.

Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz-Drager B, Helpap B, et al. Infiltrating Urothelial Carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization Classification of Tumours Pathology and Genetics: Tumours of the Urinary System and Male Genital System. Lyon: IARC Press; 2004. p. 93–109.

Abbasi M, Mirmomeni MH, Khazaei S, Ranjbaran R, Bidmeshkipoor A. Oncology Original Article Detection of p53 exon 9 gene mutation in bladder cancer by polymerase chain reaction ‑ single ‑ strand conformation polymorphism method. 2017; 69(1): 47–51.

Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

Carcinogenesis. 2006; 27(3): 361–73.

Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017; 24(10): 730–4.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide012 : Sources, methods and major patterns in GLOBOCAN 2. Int J Cancer. 2015; 136: E359-86.

Cheng ML, Iyer G. Novel biomarkers in bladder cancer. Vol. 36, Urologic Oncology: Seminars and Original Investigations. 2018.

Otsuka M, Taguchi S, Nakagawa T, Morikawa T. Clinical significance of random bladder biopsy in primary T1 bladder cancer. 2018; 665–70.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, et al. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: Implications for perioperative anti-FGFR3 treatment. Ann Oncol. 2016; 27(7): 1311–6.

Van Rhijn BWG, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004; 64(6): 1911–4.

Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University